Escitalopram

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Escitalopram

Examples of brand names: Cipralex [DE]

ATC code: N06AB10

Main use (for orientation): Depression; anxiety

Documented research summary

CL10 included people treated with citalopram/escitalopram and found increased concentrations with CBD. No separately verified percentage change in escitalopram AUC; do not present open-label sequential citalopram pharmacokinetic study CL11 as a pure escitalopram study.

Uncertainties and limitations

The rat experiment shows behavioural change, not proven benefit of combined human treatment.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0032

Type of result: Positive finding / indication

Observation: Citalopram measurements increased in the combined sample.

Mechanism: CYP2C19/CYP3A4 inhibition plausible

Study type: Small clinical ancillary investigation

Context studied: Shared exploratory subgroup of six people (15–24 years) receiving citalopram or escitalopram from an open-label study of 31 people in total. CBD capsules (>99.9%) starting at 200 mg/day, all reaching 600 mg/day by week 4; three increased to 800 mg/day by week 8. Measurements at baseline and weeks 4, 8 and 12.

Clinical interpretation: Possible; increase in adverse effects unclear

Limitations and uncertainties: No separate robust effect estimate per medicine and not an AUC study. Samples at 8–10 a.m. with usual individual administration times, not established as standardised trough concentrations. Antidepressant adherence mainly self-reported. Internal contradiction in the original: Table 2/footnote lists five escitalopram and one citalopram participant, whereas a results sentence reverses the numbers; keep subgroup allocation unresolved.

Original sources for this finding: Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People [CL10]

References and access status

[CA_L_D0091] ESCITALOPRAM OXALATE (ESCITALOPRAM) TABLET, FILM COATED [APHENA PHARMA SOLUTIONS - TENNESSEE, LLC ]

Original source / bibliographic reference

Authors: Aphena Pharma Solutions - Tennessee, LLC

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL10] Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People

Original source / bibliographic reference

Authors: Anderson LL; Doohan PT; Oldfield L; Kevin RC; Arnold JC; Berger M; Amminger GP; McGregor IS

Year: 2021

Source type: In-vitro study plus a small accompanying clinical investigation

DOI: 10.1097/JCP.0000000000001427

PMID: 34121064

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_40090594] Co-treatment with cannabidiol and escitalopram in ineffective doses induces antidepressant effect in maternally separated male adolescent rats.

Original source / bibliographic reference

Authors: Dragon J, Gołyszny M, Obuchowicz E.

Year: 2025

Source type: Journal Article

DOI: 10.1016/j.pbb.2025.174000

PMID: 40090594

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility